Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...
Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...
Mineralocorticoid receptor antagonists (MRAs) are still finding their place in nephrology. Many of us relegate them to the bottom of our therapeutic bag for use only after we've exhausted other ...
A multi-center study of more than 3,000 people with high blood pressure and brain aneurysms found that the use of RAAS inhibitors, a class of blood pressure lowering medications, reduced the risk of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback